Dextran 40 Plus Ringer's Lactate Vs. Ringer's Lactate Alone for Fluid Resuscitation in Acute Pancreatitis

Launched by SATU MARE COUNTY EMERGENCY HOSPITAL · Feb 13, 2025

Keywords

ClinConnect Summary

This clinical trial is studying whether a mixture of two fluids, Dextran 40 and Ringer's lactate, can help patients with mild to moderate acute pancreatitis recover better than just using Ringer's lactate alone. The researchers want to find out if this combination can improve patient outcomes by reducing inflammation, the risk of organ failure, and the need for intensive care. Participants in the trial will either receive the combination of Dextran 40 and Ringer's lactate or Ringer's lactate by itself. They will have blood tests every day to monitor their inflammation levels and how their organs are functioning, as well as track any changes in their condition.

To take part in this study, you must be an adult (18 years or older) diagnosed with mild or moderate acute pancreatitis and willing to give your consent. However, pregnant individuals and those with certain health issues that could complicate the treatment will not be eligible. This trial is currently recruiting participants and aims to find the best way to help people with this condition recover faster and avoid serious complications.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • adults (≥18 years) diagnosed with mild or moderate acute pancreatitis
• • must provide written informed consent for study participation.
• Exclusion Criteria:
• • patients who decline to provide informed consent.
• • patients are non-compliant with treatment and follow-up visits.
• • pregnant individuals.
• • patients requiring concomitant treatment that is contraindicated within the study protocol.
• • patients who develop conditions that contraindicate the administration of the investigational medication.
• • patients experiencing severe adverse reactions necessitating treatment discontinuation.